NASDAQ$HRTX
Heron Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
HRTX reported Q4 2024 revenue of $144.2M, net income of $3.6M.
For Q4 2024, HRTX reported Revenue was $144.2M, net income was $3.6M. Management discusses operating trends, liquidity, and outlook in the filing.
- Revenue $144.2M for Q4 2024.
- Net income $3.6M.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Heron Therapeutics · Revenue · Quarterly
$144M
Revenue by segment
Heron Therapeutics · $31.4M total across 4 segments · Q3 2023
- CINVANTI$23.3M+9.9%74.2%
- ZYNRELEF$4.4M+63.0%14.0%
- SUSTOL$3.4M+25.9%10.8%
- APONVIE$300K—1.0%
Forward guidance
The filing discusses operating priorities, capital allocation, and demand trends.
Tailwinds
- Management outlines strategic priorities and cost actions.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
30 / 63 earnings
Positive
+57.6%
Q3 2023
Best reaction
-42.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -21.1% | -29.8% | -66.3% | |
| Q4 2025 | +12.4% | +6.5% | -27.8% | |
| Q3 2025 | -1.8% | -6.8% | +11.0% | |
| Q1 2025 | +13.8% | -0.9% | -6.1% | |
| Q4 2024 | +19.9% | +49.1% | +32.2% | |
| Q3 2024 | -34.2% | -35.3% | -13.0% | |
| Q2 2024 | -24.0% | -24.7% | -31.6% | |
| Q1 2024 | +6.0% | -2.5% | +27.8% | |
| Q4 2023 | +24.9% | +27.0% | +22.0% | |
| Q3 2023 | +57.6% | +98.2% | +230.9% | |
| Q2 2023 | +3.4% | +1.9% | -21.6% | |
| Q1 2023 | -42.9% | -48.6% | -49.4% | |
| Q4 2022 | -3.3% | -18.3% | +40.1% | |
| Q3 2022 | -12.0% | +0.6% | -20.5% | |
| Q2 2022 | +31.7% | +48.5% | +33.6% | |
| Q1 2022 | -14.8% | -12.7% | -34.3% | |
| Q4 2021 | -23.8% | -29.7% | -24.6% | |
| Q3 2021 | +0.8% | +10.1% | -24.0% | |
| Q2 2021 | -0.3% | -6.4% | -1.4% | |
| Q1 2021 | +11.1% | -16.7% | -11.2% | |
| Q4 2020 | +1.1% | +1.3% | -14.7% | |
| Q3 2020 | -5.1% | -0.1% | +1.5% | |
| Q2 2020 | -9.4% | -8.3% | -18.8% | |
| Q1 2020 | +2.4% | +7.2% | +34.1% | |
| Q4 2019 | -1.0% | -11.4% | -41.6% | |
| Q3 2019 | -2.3% | +4.8% | +24.1% | |
| Q2 2019 | +0.5% | +10.3% | +10.3% | |
| Q1 2019 | +6.3% | +7.0% | +4.6% | |
| Q4 2018 | -1.4% | -1.8% | -15.3% | |
| Q3 2018 | +3.8% | -4.6% | -8.1% | |
| Q2 2018 | +2.5% | +1.8% | -2.6% | |
| Q1 2018 | +1.2% | +4.3% | +0.3% | |
| Q4 2017 | -10.2% | -6.2% | +21.9% | |
| Q3 2017 | -0.3% | +1.9% | -4.2% | |
| Q2 2017 | -1.6% | -0.6% | +0.9% | |
| Q1 2017 | -9.3% | -8.9% | -13.7% | |
| Q4 2016 | +0.4% | +3.2% | +6.5% | |
| Q3 2016 | +13.3% | +7.7% | +7.3% | |
| Q2 2016 | +5.1% | +8.0% | -2.4% | |
| Q1 2016 | -14.9% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | -1.5% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | +3.7% | — | — | |
| Q3 2013 | +2.2% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +6.8% | — | — | |
| Q4 2012 | -2.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -5.9% | — | — | |
| Q1 2012 | +2.3% | — | — | |
| Q4 2011 | +18.2% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +3.6% | — | — | |
| Q1 2011 | +5.3% | — | — | |
| Q4 2010 | -21.3% | — | — | |
| Q3 2010 | -26.9% | — | — | |
| Q2 2010 | -4.7% | — | — | |
| Q1 2010 | -12.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro